Trigger mechanism provides 'quality control' in cell division

November 22, 2010

SALT LAKE CITY, November 22, 2010 --Researchers from Huntsman Cancer Institute (HCI) at the University of Utah report that they have identified a previously undiscovered trigger mechanism for a quality control checkpoint at the very end of the cell division process in a paper to be published in the November 29 issue of The Journal of Cell Biology and online today. This trigger mechanism monitors whether the cell's nucleus, where the DNA resides, has the proper structure and delays cell division if the structure is not correct. Previously discovered triggers have been associated with improper DNA division and distribution, but not the nuclear structure.

"Much cancer research centers on the question 'How does cancer start?' And it's usually when some normal process that's vital for cell division is somehow not carried out correctly," says Katharine Ullman, Ph.D., professor in the Department of Oncological Sciences, HCI investigator, and senior author on the paper. "Mistakes in this stage of quality control and this particular trigger could be one of the contributing factors to the initiation of cancer. It's not going to be the only one, but it will help us ask additional important questions about how cancer forms."

Research in the Ullman Lab focuses on the nuclear pore complex (NPC), a cellular structure that is embedded in membranes that enclose the nucleus. NPCs serve as gateways for material moving between the nucleus and the rest of the cell, and they are also important to nuclear organization. More recently, roles for NPC components are emerging in cell division. Cell division requires duplication of the cell's DNA, dissolution of the nucleus--including NPCs themselves--regrouping the duplicated DNA into two identical packages, and re-formation of the two new nuclei before cell separation occurs. In this study, the researchers examined cells that had been depleted of a component of the NPC called Nup153.

"We found that in its absence, a set of architectural elements at, and associated with, the nuclear pore weren't being put back together correctly during nuclear reformation," says Ullman. "At the same time, we saw another protein, Aurora B, stopping the cell cycle from proceeding." She continues that other experimental strategies that interfered with reformation of this aspect of nuclear architecture similarly affected Aurora B. Aurora B has been widely studied as a target for new chemotherapy drugs. When activated, it conveys signals beginning and ending many steps of cell division.

"The connection we recently found is specific to the last stage of cell division called abscission. Abscission is the point of no return in the process of one cell becoming two," says Ullman. "Although Aurora B needs to be activated and inactivated throughout the cell division process, the impact of the missing Nup153 protein occurred only at this very late stage."

Ullman plans to pursue further research into the details of the molecular pathway between Nup153 and Aurora B. "At present, we can see that the two connect, but we do not understand the steps of the pathway," she says.
-end-
Douglas R. Mackay, Ph.D., and Masaki Makise, Ph.D., both postdoctoral fellows in the University of Utah Department of Oncological Sciences, co-authored the study. Funding support was provided by the American Cancer Society, the National Institutes of Health, the Leukemia and Lymphoma Society, and Huntsman Cancer Foundation.

The mission of Huntsman Cancer Institute (HCI) at The University of Utah is to understand cancer from its beginnings, to use that knowledge in the creation and improvement of cancer treatments, to relieve the suffering of cancer patients, and to provide education about cancer risk, prevention, and care. HCI is a National Cancer Institute-Designated Cancer Center, which means that it meets the highest national standards for cancer care and research and receives support for its scientific endeavors. HCI is also a member of the National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of the world's leading cancer centers that is dedicated to improving the quality and effectiveness of care provided to patients with cancer. For more information about HCI, please visit www.huntsmancancer.org.

University of Utah Health Sciences

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.